ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

ACS Executive Proposes Efficiency Plan, Critics Fear Erosion Of Local Influence

May 1, 1998

NCI To Fund Partnerships Between Cancer Centers and Minority Institutions

November 12, 1999

In Brief: Three NCI Basic Science Centers Rank In Index Of Citations; Novello: Help More Smokers Quit

August 2, 1991

ORI Bars Cleveland Researcher From Federal Funding

March 24, 1995

Breast MRI Recipients More Likely To Choose Mastectomy

July 31, 2009

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008